GET DAILY SIGNALSWhy Is Exagen Inc. (XGN) Stock Down -23.10% Today?
Key Takeaways
- Exagen Inc. (XGN) shares fell 23.10% to $5.46 in Tuesday morning trading, down $1.64 from the prior session's $7.10 close.
- The primary catalyst was a third-quarter report that showed a wider-than-expected per-share loss and a larger operating loss, even as revenue grew 7% to $18.4 million.
- A second, reinforcing driver: the company filed a new $150 million shelf registration that includes a $50 million at-the-market stock program — a large potential dilution overhang for a company with a roughly $130 million market value.
- Trading was heavy, with about 154,600 shares changing hands in the first 15 minutes versus a three-month average daily volume near 330,000 shares.
- The selloff appears company-specific rather than sector-driven; the shares carry a beta of 2.24, meaning they typically amplify broader market swings.
- News Significance Score: 70/100 — Material earnings and financing news combined with a decline nearly six times the stock's typical daily move.
- What traders are watching next: commentary from the morning earnings call, any sign of selling under the new at-the-market facility, the implied fourth-quarter revenue range, and the December 15 myositis webcast.
- Investors can dig into Price Targets, Earnings, and Forecast data for XGN on the dedicated Tickeron pages.
- Readers can also explore Trending AI Robots to see which automated strategies are performing best in the current market.
Opening Summary
Exagen Inc. (XGN) is a San Diego County–based diagnostics company that sells the AVISE CTD blood test and related panels to rheumatologists hunting for lupus, rheumatoid arthritis and Sjögren's disease. On Tuesday morning the stock was trading at $5.46, down 23.10% from Monday's close of $7.10, having opened at $6.00 and traded as low as $5.395 in the first quarter hour. The direction is unambiguously lower. Markets had a clear, verifiable trigger: a quarterly report released before the opening bell that missed on profitability, paired with a fresh shelf registration and at-the-market equity program that revived dilution concerns.
Earnings Miss and a Wider Operating Loss
Third-quarter revenue rose 7% year over year to $18.42 million, with gross margin improving to 58.8% and the trailing twelve-month average selling price per AVISE CTD test climbing to $451 — the fourteenth consecutive quarter of growth. Revenue landed essentially in line with the roughly $18.5 million consensus, so the top line was not the problem.
Profitability was. The net loss of $6.34 million, or $0.25 per share, was wider than the roughly $0.19 loss analysts modeled, despite narrowing from $7.09 million a year earlier. Operating expenses rose about 16% to $15.24 million, lifting the operating loss to $4.41 million from $3.10 million, and adjusted EBITDA slipped to a $1.93 million deficit. That combination — modest top-line growth against accelerating spending — is the part of the release that did the damage. Management reiterated full-year revenue guidance of $72 million to $75 million, a neutral detail rather than a rescue, since nine-month revenue of $55.7 million implies a fourth-quarter range of roughly $16.3 million to $19.3 million.
A $150 Million Shelf and $50 Million ATM Revive Dilution Concerns
The second pressure point was balance-sheet related. The company registered up to $150 million of securities on a new shelf and disclosed a sales agreement, dated November 9, covering up to $50 million of common stock sold at prevailing prices through TD Securities. With cash down to $28.1 million from $35.7 million a year earlier and $6.5 million already raised under the prior facility during the quarter, the filing signals continued reliance on equity capital to fund commercial expansion and the early-2027 myositis launch. For a company of this size, a $50 million at-the-market program is meaningful and gives short sellers a straightforward thesis.
Market Context and Trading Activity
Participation was elevated from the opening bell: roughly 154,600 shares traded in the first 15 minutes, close to half a normal full day's volume. The move was company-specific — nothing in the release points to an industry-wide read-through, and there was no broad macro release driving small-cap diagnostics. The stock now trades well below its 50-day moving average near $7.90 and sits roughly 30% under its 52-week high of $10.27, though still far above the $2.59 low.
Context matters for the tape. Shares fell 10.7% on November 5 and 23.6% on November 6 before rebounding 22.2% on Monday ahead of the print. Today's drop retraces that pre-earnings rally and is the third session in five with a double-digit swing, consistent with an illiquid, headline-sensitive micro-cap rather than a smooth repricing.
News Significance Score
The scale runs from 0 — no meaningful news and a move that is ordinary for the stock — to 100 — transformative news and an extreme, rare price move. This event lands at 70 out of 100. The verified news was substantive: an earnings per-share miss, a wider operating loss, and a $150 million shelf with a $50 million at-the-market facility, all material relative to a company of this size. The price reaction was also unusual: today's 23.10% decline is roughly 5.8 times the stock's typical daily move of about 4.0% over the past 69 sessions, and only two sessions in that stretch were as large or larger. Strong news plus a rare move produces the high score.
What Comes Next for XGN
The next scheduled checkpoint is the December 15 educational webcast on myositis, the company's first standalone new product, with validation submitted to New York State by late January 2027 for an early-2027 launch. Fourth-quarter results and 2027 guidance will be the real test of whether spending is translating into durable volume and price gains. Management also participates in the Canaccord Genuity MedTech & Diagnostics Conference on November 11 and the Craig-Hallum Alpha Select Conference on November 17, offering near-term opportunities for clarification. Investors should weigh the trajectory of cash and share count, the variability of prior-period collections that have flattered recent average selling prices, payer coverage decisions, and the ever-present risk that reimbursement or guideline progress stalls.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions earn a place in its curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the featured lineup changes as conditions shift. For traders navigating volatile single names like this one, reviewing the current leaders is a practical way to compare approaches before committing capital.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XGN in -31.73% downward trend, sliding for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XGN declined for three days, in 291 of 333 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In 80 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 31 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XGN's RSI Indicator exited the oversold zone, 33 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for XGN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 161 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.522) is normal, around the industry mean (67.298). P/E Ratio (-7.085) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. XGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
Industry MedicalSpecialties
Advertisement